Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
36.92 (USD) • At close January 3, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Supernus Pharmaceuticals, Inc. |
Symbool | SUPN |
Munteenheid | USD |
Prijs | 36.92 |
Beurswaarde | 2,038,696,556 |
Dividendpercentage | 0% |
52-weken bereik | 25.53 - 39.37 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Jack A. Khattar |
Website | https://www.supernus.com |
An error occurred while fetching data.
Over Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)